Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alliance Pharma PLC (GB:APH)
LSE:APH
APH Stock Chart & Stats
Day’s Range― - ―
52-Week Range24.55p - 62.00p
Previous CloseN/A
Volume68.57K
Average Volume (3M)6.07M
Market Cap
£332.45M
Enterprise Value298.21M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Mar 25, 2025EPS Estimate
2.5Last Dividend Ex-Date
Jun 22, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding540,565,550
10 Day Avg. Volume843,998
30 Day Avg. Volume6,069,523
Standard Deviation0.11
R-Squared0.12
Alpha-0.00174
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.96
Price to Cash Flow (P/CF)11.60
P/FCF Ratio9.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
62.67pPrice Target Upside1.90% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Alliance Pharma News
PremiumCompany Announcements
Alliance Pharma Reports Stable 2024 Revenue with Strong Brand Performances
PremiumCompany Announcements
Alliance Pharma Announces Recommended Acquisition by Aegros BidcoPremiumCompany Announcements
Alliance Pharma Reports Change in Major Shareholder Holdings
PremiumCompany Announcements
Alliance Pharma Sees Major Share Ownership Shift
PremiumCompany Announcements
Alliance Pharma Reports Steady Growth in 2024
PremiumCompany Announcements
Alliance Pharma Announces Upcoming Financial Results
PremiumCompany Announcements
Alliance Pharma Confronts AGM Dissent
PremiumCompany Announcements
Alliance Pharma Sustains Growth Amidst Challenges---
Bulls Say, Bears Say
Bulls Say
AcquisitionDBAY's initial offer was raised by 20% to 62.5p, and the acquisition of Alliance is expected to complete.
Debt And LeverageNet debt and leverage were slightly better than expected, with further reductions anticipated, targeting leverage around 1.5x.
Product PerformanceKelo-Cote franchise revenues increased significantly, boosted by strong in-market sales in China, outperforming market growth.
Bears Say
Product StrugglesKey consumer products like Nizoral and Amberen continue to struggle and were below expectations.
Revenue DeclineRevenues declined 1% to £180.3m, which is below consensus expectations.
Supply Chain IssuesRestructuring of the China supply chain for key product Kelo-Cote is taking longer than expected.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.39% Mutual Funds
― Other Institutional Investors
99.54% Public Companies and
Individual Investors
APH FAQ
What was Alliance Pharma PLC’s price range in the past 12 months?
Alliance Pharma PLC lowest share price was 24.55p and its highest was 62.00p in the past 12 months.
What is Alliance Pharma PLC’s market cap?
Alliance Pharma PLC’s market cap is £332.45M.
When is Alliance Pharma PLC’s upcoming earnings report date?
Alliance Pharma PLC’s upcoming earnings report date is Mar 25, 2025 which is in 36 days.
How were Alliance Pharma PLC’s earnings last quarter?
Alliance Pharma PLC released its earnings results on Sep 30, 2024. The company reported 0.018p earnings per share for the quarter, beating the consensus estimate of N/A by 0.018p.
Is Alliance Pharma PLC overvalued?
According to Wall Street analysts Alliance Pharma PLC’s price is currently Undervalued.
Does Alliance Pharma PLC pay dividends?
Alliance Pharma PLC pays a Annually dividend of 1.183p which represents an annual dividend yield of N/A. See more information on Alliance Pharma PLC dividends here
What is Alliance Pharma PLC’s EPS estimate?
Alliance Pharma PLC’s EPS estimate is 2.5.
How many shares outstanding does Alliance Pharma PLC have?
Alliance Pharma PLC has 540,565,550 shares outstanding.
What happened to Alliance Pharma PLC’s price movement after its last earnings report?
Alliance Pharma PLC reported an EPS of 0.018p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.181%.
Which hedge fund is a major shareholder of Alliance Pharma PLC?
Currently, no hedge funds are holding shares in GB:APH
---
Alliance Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
62.67p (1.90% Upside)
62.67p (1.90% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.22%
12-Months-Change
Fundamentals
Return on Equity
-13.44%
Trailing 12-Months
Asset Growth
-22.46%
Trailing 12-Months
Company Description
Alliance Pharma PLC
Alliance Pharma PLC is a player in the healthcare market. The company's business includes acquisition, marketing, and distribution of pharmaceutical products. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol.
---
APH Stock 12 Month Forecast
Average Price Target
62.67p
▲(1.90% Upside)
Technical Analysis
Best Analysts Covering APH
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+51.80%
reiterated a buy rating 8 months ago
Copying Paul Cuddon's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +51.80% per trade.
---